Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ars Pharmaceuticals Inc (SPRY)

Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ars Pharmaceuticals Inc 11682 El Camino Real Suite 120 San Diego CA 92130 USA

https://ars-pharma.com Employees: 26 P: 858-771-9307

Description:

ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites. ARS Pharmaceuticals Inc., formerly known as Silverback Therapeutics Inc., is based in SEATTLE.

Key Statistics

Overview:

Market Capitalization, $K 1,316,857
Enterprise Value, $K 1,245,887
Shares Outstanding, K 97,185
Annual Sales, $ 30 K
Annual Net Income, $ -54,370 K
Last Quarter Sales, $ 2,070 K
Last Quarter Net Income, $ -19,130 K
EBIT, $ -60,510 K
EBITDA, $ -67,320 K
60-Month Beta 0.90
% of Insider Shareholders 40.10%
% of Institutional Shareholders 68.16%
Float, K 58,214
% Float 59.90%
Short Volume Ratio 0.31

Growth:

1-Year Return 187.23%
3-Year Return 88.46%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.20 on 11/13/24
Next Earnings Date N/A
Earnings Per Share ttm -0.51
EPS Growth vs. Prev Qtr -53.85%
EPS Growth vs. Prev Year -25.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

SPRY Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -22.55%
Return-on-Assets % -21.82%
Profit Margin % -181,233.33%
Debt/Equity 0.00
Price/Sales 44,672.70
Price/Cash Flow N/A
Price/Book 6.65
Book Value/Share 2.07
Interest Coverage -0.15
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar